Pharmaceuticals

One-time single eye injection of Jetrea® recognized as clinically and cost-effective treatment for eligible patients with vitreomacular traction, including macular hole Jetrea® is the first and only approved pharmacological treatment in the UK for this sight-threatening condition Vitreomacular traction with macular hole is an age-related eye condition that can cause loss of vision and impaired […]

Great Place to Work® recognizes Novartis for outstanding workplace culture  Inclusion in list of best employers based on survey of 7,200 companies around the world Novartis ranked high for the pride associates take in their work, their teams and the organization Basel, October 22, 2013 – Novartis is pleased to announce that it has been […]

California, USA, October 15, 2013 – Sandoz welcomes California Governor Jerry Brown’s veto of legislation that threatened to restrict patient access to biosimilars – high-quality follow-on versions of existing biologic medicines to treat complex disorders including cancer and autoimmune diseases. Mark McCamish, global head of Sandoz Biopharmaceutical Development, who wrote a personal letter to the governor […]

Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment[1] Omalizumab 300 mg was nearly twice as effective in improving patients’ quality of life within 12 weeks of treatment versus placebo[1] ASTERIA I is the final omalizumab CSU registration study […]

Secukinumab (AIN457) patients’ skin cleared faster and for longer than Enbrel® (etanercept) patients, beginning as early as Week 2[1] Study also showed twice as many secukinumab patients experienced clear or almost clear skin by Week 12 versus Enbrel[1] Head-to-head study of secukinumab and Enbrel part of largest clinical program completed in moderate-to-severe plaque psoriasis with […]